Last reviewed · How we verify
Renin-Angiotensin (RAAS) alone
RAAS inhibitors block the renin-angiotensin-aldosterone system to reduce blood pressure and protect organs from hypertension-related damage.
RAAS inhibitors block the renin-angiotensin-aldosterone system to reduce blood pressure and protect organs from hypertension-related damage. Used for Hypertension, Heart failure, Chronic kidney disease.
At a glance
| Generic name | Renin-Angiotensin (RAAS) alone |
|---|---|
| Also known as | Lispril, Enalapril, Perindopril, Losarta, Valsar etc., |
| Sponsor | James A. Tumlin, MD |
| Drug class | RAAS inhibitor (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist) |
| Target | Renin-angiotensin-aldosterone system components (ACE, AT1 receptor, renin, or aldosterone receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that regulates blood pressure and fluid balance. RAAS inhibitors (including ACE inhibitors, ARBs, direct renin inhibitors, and aldosterone antagonists) interrupt this pathway at various points, reducing vasoconstriction and aldosterone-mediated sodium retention, thereby lowering blood pressure and reducing proteinuria. These agents are used alone or in combination for cardiovascular and renal protection.
Approved indications
- Hypertension
- Heart failure
- Chronic kidney disease
- Post-myocardial infarction
- Diabetic nephropathy
Common side effects
- Cough (ACE inhibitors)
- Hyperkalemia
- Dizziness
- Fatigue
- Angioedema
Key clinical trials
- International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response (PHASE2, PHASE3)
- Novel Experimental COVID-19 Therapies Affecting Host Response (PHASE2, PHASE3)
- Preserving Kidney Function in Children With Chronic Kidney Disease
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy (PHASE4)
- Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Renin-Angiotensin (RAAS) alone CI brief — competitive landscape report
- Renin-Angiotensin (RAAS) alone updates RSS · CI watch RSS
- James A. Tumlin, MD portfolio CI